Kalif Eliyahu Sharon 4

What Happened

• Kalif Eliyahu Sharon, Chief Financial Officer of Teva Pharmaceutical Industries Ltd (TEVA), sold 153,251 shares on May 14, 2026 in an open-market/private sale for total proceeds of $5,457,375.
• The reported weighted-average price was $35.61 per share; the shares were sold in multiple trades at prices ranging from $35.59 to $35.80.

Key Details

• Transaction date: May 14, 2026.
• Reported weighted-average price: $35.61; trade price range: $35.59–$35.80 (seller will provide a per-price breakdown on request) [F3].
• Total proceeds: $5,457,375.
• Transaction type/code: Sale (S); effected pursuant to a Rule 10b5-1 trading plan adopted November 26, 2025 [F2].
• ADS note: Teva ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share [F1].
• Filing date: May 18, 2026 — appears timely (filed within the Form 4 two-business-day window).
• Shares owned after the transaction: not disclosed in the provided filing.

Context

• The sale was executed under a pre-established Rule 10b5-1 plan, which typically schedules trades in advance and can indicate the sale was pre-planned rather than a real-time decision based on inside information. Sales by executives are common and do not by themselves signal company performance or management sentiment.